Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 55.40 0.00 07:41:53
Bid Price Offer Price High Price Low Price Open Price
54.40 57.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.72 -9.07 -8.00 120
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 55.40 GBX

Shield Therapeutics (STX) Latest News

More Shield Therapeutics News
Shield Therapeutics Investors    Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
25/6/202107:35Shield Therapeutics: poised for a US licensing deal2,647
21/5/202110:46Shield Therapeutics 3,820
06/8/202021:59Shield Therapeutics: Poised for a US deal-
22/2/202021:14Seagate Technology2,674

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 17:25:5557.00150,00085,500.00O
2021-06-24 16:50:2956.9025,00014,225.00O
2021-06-24 16:50:2958.1350,00029,062.50O
2021-06-24 16:50:2960.049,2545,555.82O
2021-06-24 16:50:2957.1350,00028,562.50O
View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 55.40p.
Shield Therapeutics Plc has a 4 week average price of 50.50p and a 12 week average price of 43p.
The 1 year high share price is 150p while the 1 year low share price is currently 32.50p.
There are currently 215,837,965 shares in issue and the average daily traded volume is 1,245,147 shares. The market capitalisation of Shield Therapeutics Plc is £119,574,232.61.
shandypants2: PATT - previously STX has stated accrufer will be priced similar to IV but without all the add on costs. However, clearly it is not that simple as the number of IV a person needs will depend on their iron levels and how quickly it is absorbed - the average is about 3 sessions. The other thing with IV is that top ups may be needed e.g. every 3 months. Again this will vary per person. Below is a quick link to an iron clinic - they charge £570 per session so 3 sessions would be £1,700. About $2,500. 4 months of Accrufer is $2k and 6 months is $3k. So there is your comparison. I think the USP for Accrufer is it's simplicity. No pre tests , no hospital visits, no monitoring etc. BTW i'm not having a pop but your 1 month comparison is just wrong. When H2H studies were undertaken with IV Accrufer was c75% as effective after 12 weeks but comparable after 24 weeks (this was an unfair study for STX as patients could have as many IV top ups as required, so to get that close after 12 weeks is still a positive). STX estimate a 4 month treatment per patient. hxxps://
frrinvest: Accrufer not only wins on costs but other benefits too - of administering from home versus going to hospital especially in the Covid-19 pandemic which is here to stay for a long time it appears. A win win. On a separate note, the Chinese is a big market too (probably even bigger than USA) and they are currently undergoing their own studies and approval process. Only a matter of time and when it comes through the share price could be on an another level. However, STX may well be a history by then as someone can take it over. Another win win. Really cheap at this level imho. DYOR!
78steve: I wonder how often will they update market on sales progress. I suppose if we see share price moving up over coming months we know sales doing well as people in the know pile in and drive price up.
david gruen: 24/06/2021 7:00am UK Regulatory (RNS & others) Shield Therapeutics (LSE:STX) Intraday Stock Chart Thursday 24 June 2021 Click Here for more Shield Therapeutics Charts. TIDMSTX RNS Number : 9027C Shield Therapeutics PLC 24 June 2021 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") US launch of Accrufer(R) confirmed for July 1, 2021 London, UK, June 24, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), confirms that, in line with prior guidance, it will launch Accrufer(R) in the US on July 1, 2021. Launch stocks of Accrufer(R) are currently being distributed through the wholesaler channels and will be available to doctors and other prescribers in all parts of the US by July 1, 2021. A sales force including 30 sales representatives has been recruited and trained and will be starting to contact key prescribers during next week. Greg Madison, CEO of Shield, said "We are pleased to make Accrufer(R) available to physicians and their patients in the US. Iron deficiency and iron deficiency anemia are significant challenges for millions of patients. Accrufer(R) represents a novel form of oral iron which offers clinical effectiveness while being well tolerated in clinical trials, and has the potential to be a significant advance for those patients in the US."
kalkaar: from Dr. Susie Jana, Healthcare Analyst at Edison: Pharma & biotech - Mcap £123m - Price 57p - Flash note Greg Madison succeeds Tim Watts as CEO: Shield Therapeutics (STX) has announced the appointment of a new chief executive officer (CEO), Greg Madison, with effect from 1 June 2021. Greg is a seasoned CEO with previous experience of the US iron deficiency market. Notably, he led the transformation of Keryx Biopharmaceuticals (2015–18) into a US commercial stage company focused on Auryxia (ferric citrate), an oral product for the treatment of iron deficiency anaemia and hyperphosphatemia. Given the primary focus for STX now is to establish and expand its US-based operations ahead of a Q221 launch of lead asset Accrufer (oral ferric maltol), the appointment of a US-based CEO makes sense in our view. Our valuation of STX is unchanged at £505.7m or 234p/share.
purchaseatthetop: Thanks Jerrymouse....I agree with you in that there is NOTHING wrong with a profit. The only thing bad about a profit is when you sell and then the price goes up another 10,000%. That is sickness and regret in spades. ITX is a monster and I started at 2p in Dec 2020. My other big plays are AGL and more recently ENET. However, I am going to hold long and strong with STX. The market cap is small compared to the cash generation that will kick in in 2023/4. Yes, money can be made in trading the dips, but I prefer just to add in the dips and avoid the horror of, for example, trading when the share price takes off and you cannot get the shares back. Good luck with your trading strategy. I hope it works and I also hope for dips. I enjoy them for buying more value. PATT
purchaseatthetop: PATT called it spot on. Should be a boost to the share price today. Over 60p. Sorry....that is speculation of an RNS and a share price over 60p in one post. Damn!
ttny2004: Shield Therapeutics PLC Commencement of trading on the OTCQX Best MarketSource: UK Regulatory (RNS & others)TIDMSTXRNS Number : 7260YShield Therapeutics PLC17 May 2021Shield Therapeutics plc("Shield", the "Company" or the "Group")Commencement of trading on the OTCQX Best Market in the United StatesLondon, UK, 17 May 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), announces that trading in the Company's Ordinary Shares of nominal value of GBP0.015 each ("Ordinary Shares") will begin today on the OTCQX Best Market ("OTCQX") in the United States, under the ticker symbol "SHIEF".By trading on the premium OTCQX, Shield's shares will be available to US investors during US working hours and priced in US dollars and has the potential to increase liquidity in Shield's shares on AIM. The OTCQX is designed for established companies. Foreign Private Issuers, such as Shield, that trade on the OTCQX are exempt under the US Exchange Act Rule 12g3-2(b) from SEC reporting if they make whatever information is required by their home market regulator publicly available to US investors in English. Shield will therefore face no extra reporting obligations and incur minimal ongoing costs as a result of the Company's Ordinary Shares being traded on the OTCQX.Shield has retained MCAP LLC to act as the Company's OTCQX advisor. MCAP is a US broker-dealer that provides institutional securities services and electronic market making. MCAP also acted as the Company's OTCQX sponsor.Shield's Ordinary Shares will continue to trade on the London Stock Exchange's AIM Market under the symbol "STX".Commenting on this, Tim Watts, Shield CEO, said: "With the upcoming launch of Accrufer(R) in the US I believe that Shield will be of increasing relevance to US based investors. By making our shares available on the OTCQX Best Market many US investors should find it easier to buy and sell Shield shares than they would through AIM. Shield's existing shareholders should benefit from this as liquidity increases."
purchaseatthetop: donaferentes....fully agree that STX may be a 10 bagger based on US roll out. It is why I invested. I would have put more into AGL but I limit myself to 20% of my SIPP portfolio into any one share (because we know that there are unknown unknowns)and so I was looking for the next best pharma alternative. Bingo STX. I expect great things from STX. Next week news of US roll out following the new NED's who would not have come onboard without certainty of this rollout (share up to 65p) then actual earnings starting H2 2021 (share up to 100p) then solid rising as global incomes mushroom. For present PI's the failure of the previous US plans are a pot of gold (at the cost of previous LTH's) as the margins (as you correctly point out) are 90% when a licensing deal might be 15%. Bingo.
shandypants2: In 2020 the 4 NEDS earned a combined £232k for essentially part time roles. Peter Llewellyn-Davies is in charge of the audit committee which covers risk mgmt. At some point in 2020 when things were quite healthy and the share price was well above £1 could he not have identified a massive cash shortfall if an US deal was not completed - especially as one company had already pulled out after advanced talks in March/April last year. A smallish placing at that point would have strengthened the balance sheet and potentially improved STX's bargaining position. Peter Llewellyn-Davies earned £48k in 2020 (£46k in 2019) from STX. As per the accounts he held 10k shares. In the recent placing he took up the 2 for 17 share option and acquired an additional 1,176 shares. The cost was £352.80. Rolf Hoffman is has Commercial Operations US experience and is chair of the Remuneration Committee. He earned £45k last year. Could he not have explained how the sales process worked in the US 18 months ago, so the decision to go it alone could have been done from a position of strength. He has no shares and declined to participate in the recent heavily discounted placing. I strongly suspect CEO will leave next month as his 12 month fixed term contract is up for renewal. These 2 can follow him as it is clear they add no value
Shield Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 07:10:06